Last reviewed · How we verify

Saniona — Portfolio Competitive Intelligence Brief

Saniona pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tesomet "High dose" in fasted condition Tesomet "High dose" in fasted condition marketed
Tesomet "High dose" in fed condition Tesomet "High dose" in fed condition marketed Monoamine reuptake inhibitor + biguanide combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase Endocrinology / Obesity / Diabetes
Tesomet "Low dose" in fasted condition Tesomet "Low dose" in fasted condition marketed Monoamine reuptake inhibitor + biguanide combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase Endocrinology / Obesity

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Saniona:

Cite this brief

Drug Landscape (2026). Saniona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/saniona. Accessed 2026-05-14.

Related